Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.780
+0.020 (2.60%)
At close: Nov 20, 2024, 4:00 PM
0.746
-0.034 (-4.37%)
Pre-market: Nov 21, 2024, 7:14 AM EST

Company Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.

The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.
Biofrontera logo
Country United States
Founded 1997
IPO Date Oct 29, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 85
CEO Hermann Luebbert

Contact Details

Address:
120 Presidential Way, Suite 330
Woburn, Massachusetts 01801
United States
Phone 781-245-1325
Website biofrontera-us.com

Stock Details

Ticker Symbol BFRI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001858685
CUSIP Number 09077D100
ISIN Number US09077D2099
Employer ID 47-3765675
SIC Code 2834

Key Executives

Name Position
Dr. Hermann Luebbert Ph.D. Chief Executive Officer, President and Executive Chairman
Eugene Frederick Leffler III Chief Financial Officer
Erica F. Gates CPA, M.B.A. Senior Director of Finance and Principal Accounting Officer
Jon Lyons M.B.A., Ph.D. Vice President of Scientific and Medical Affairs
Alycia Torres Vice President of Administration
Daniel Hakansson J.D. General Counsel and Head of Compliance
Mark Baldyga Vice President of Sales and Marketing

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 13, 2024 S-8 Securities to be offered to employees in employee benefit plans
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 1, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 8-K Current Report
Oct 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals